ArticleCytotechnology2025
Combined anti-SPP-1 and anti-CTLA-4 immunotherapy enhances anti-tumor efficacy in hepatocellular carcinoma via IL-6/STAT3 pathway modulation.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, and secreted phosphoprotein 1 (SPP-1) is linked to tumor progression and immune evasion. This study investigates whether anti-SPP-1 therapy can enhance the anti-tumor effects of anti-CTLA-4 immunotherapy in HCC and elucidates the underlying molecular mechanisms. Data from The Cancer Genome Atlas (TCGA) comprising 374 HCC patients were analyzed to examine SPP-1 expression and its correlation with clinical prognosis using the Kaplan-Meier survival curve and multivariate Cox regression models. Multiple bioinformatics platforms including TIMER and TISIDB were employed to assess SPP-1's role in the tumor immune microenvironment. In vivo validation was performed in H22 hepatocellular carcinoma syngeneic mouse models treated with anti-SPP-1 and anti-CTLA-4 antibodies, where tumor growth and immune cell infiltration were evaluated using flow cytometry, immunohistochemistry, and molecular interaction studies. In the 374 HCC patient cohort, high SPP-1 expression was significantly associated with advanced TNM staging, pathological grading, and vascular invasion. Lower SPP-1 expression significantly correlated with improved overall survival, disease-specific survival, and progression-free intervals, confirming SPP-1 as an independent prognostic factor in multivariate analysis. Immune infiltration analysis revealed that SPP-1 was positively correlated with immune cells and checkpoint molecules including CTLA-4. In a syngeneic tumor model, combination therapy with anti-SPP-1 and anti-CTLA-4 significantly inhibited tumor growth, increased CD8+ T cell infiltration, and promoted M1 macrophage polarization. Mechanistically, combination therapy significantly reduced IL-6 expression and suppressed STAT3 signaling, while interferon-γ levels were elevated in the combination therapy group. Co-immunoprecipitation experiments confirmed SPP-1/IL-6 protein interaction. SPP-1 serves as both a potential prognostic marker and therapeutic target for HCC. Combined anti-SPP-1 and anti-CTLA-4 therapy synergistically enhances immunotherapy efficacy by suppressing the IL-6/STAT3 pathway, offering a promising translational strategy for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.